Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026

Revolution Medicines, Inc.

2025-FY EPS reported -$5.95

Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.
Cash $2.0B; 2026 GAAP op expenses guided $1.6-$1.7B with $180-$200M stock comp.
Phase 3 RASolute 302 (daraxonrasib in 2L PDAC) readout expected H1 2026; enrollment complete.
Initiated RASolute 305 (zoldonrasib in 1L PDAC); zoldonrasib FDA Breakthrough Therapy in NSCLC.
New RAS(ON) inhibitor RMC-5127 entered clinic; new class RM-055 Phase 1 planned Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.